In our cohort, hormone receptor (HR)-negative status was independently associated with higher pCR rates, smaller tumor size was also predictive of better response, and HER2 IHC 3+ tumors demonstrated significantly better response compared with IHC 2 +/FISH-positive cases, in line with previous reports [39,40,41]. This evidence concerns the gene ERBB2 and neoplasm.